IP Library Granted Patent US 12,648,954
Granted Patent B2
US 12,648,954 · App. 17/559,598 · Granted Jun 9, 2026

Cannabinoid lozenge formulation

Inventors: Heidi Ziegler Bruun (Vejle Ost, DK); Dorthe Schackinger Boesen (Vejle, DK); Ane Eriksen (Vejle, DK)
Assignee: NORDICCAN A/S
A61K31/658A61K9/0056A61K47/02A61K47/26A61K47/38A61K47/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,648,954
App. No.
17/559,598
Granted
Jun 9, 2026
Kind
B2
Abstract

The present invention relates to a lozenge composition for controlled release of cannabinoids containing i) a master granule component including one or more solid particles and one or more cannabinoids reversibly associated with the one or more solid particles; and ii) an extragranular component blended with the master granule component that includes one or more extragranular sugar alcohols.

Claims (36)

1 . A lozenge composition for controlled release of cannabinoids comprising:

i) a master granule component consisting of one or more non-dissolved solid particles and one or more cannabinoids dissolved in a lipid carrier that is adsorbed to a surface of the one or more non-dissolved solid particles; and

ii) an extragranular component comprising one or more extragranular water-soluble ingredients,

wherein the master granule component is present in a mixture with the extragranular component in the lozenge composition, and

wherein the one or more non-dissolved solid particles are selected from one or more sugars or one or more sugar alcohols.

2 . The lozenge composition according to claim 1 , wherein the one or more sugar alcohols are selected from the group consisting of xylitol, lactitol, sorbitol, maltitol, erythritol, isomalt and mannitol, and mixtures and combinations thereof.

3 . The lozenge composition according to claim 1 , wherein the one or more sugars are selected from the group consisting of dextrose, sucrose, maltose, fructose, lactose, and mixtures and combinations thereof.

4 . The lozenge composition according to claim 1 , wherein the master granule component is a premixture of the one or more non-dissolved solid particles and the one or more cannabinoids, the one or more cannabinoids being applied to the surface of the one or more non-dissolved solid particles by means of spraying.

5 . The lozenge composition according to claim 1 , wherein the lozenge composition does not comprise a polymer carrier for the one or more cannabinoids.

6 . The lozenge composition according to claim 1 , wherein the one or more non-dissolved solid particles are agglomerated to form granules comprising the one or more cannabinoids.

7 . The lozenge composition according to claim 1 , wherein the lipid carrier comprises one or more terpenes.

8 . The lozenge composition according to claim 1 , wherein a weight ratio of the one or more cannabinoids relative to the one or more non-dissolved solid particles is from 1:30 to 1:1.

9 . The lozenge composition according to claim 1 , wherein the one or more non-dissolved solid particles of the master granule component have a volume weighted mean diameter of 10-400 μm.

10 . The lozenge composition according to claim 1 , wherein the one or more cannabinoids is selected from the group consisting of cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), and mixtures and combinations thereof.

11 . The lozenge composition according to claim 1 , wherein the one or more cannabinoids is selected from the group consisting of tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), and mixtures and combinations thereof.

12 . A powder composition for controlled release of cannabinoids comprising:

i) a master granule component consisting of one or more non-dissolved solid particles and one or more cannabinoids dissolved in a lipid carrier that is adsorbed to a surface of the one or more non-dissolved solid particles; and

ii) an extragranular component comprising one or more extragranular water-soluble ingredients,

wherein the master granule component is present in a mixture with the extragranular component in the powder composition, and

wherein the one or more non-dissolved solid particles are selected from one or more sugars or one or more sugar alcohols.

13 . The powder composition according to claim 12 , wherein a weight ratio of the master granule component relative to the extragranular component is from 1:30 to 1:2.

14 . The powder composition according to claim 12 , wherein the one or more non-dissolved solid particles comprises one or more sugar alcohols in an amount of 5 to 40% by weight of the powder composition and the one or more extragranular water-soluble ingredients comprises one or more sugar alcohols in an amount of 60 to 95% by weight of the of the powder composition.

15 . A lozenge composition for controlled release of cannabinoids comprising;

i) a master granule component premixture consisting of one or more non-dissolved solid particles and one or more cannabinoids adsorbed to a surface of the one or more non-dissolved solid particles; and

ii) an extragranular component comprising one or more extragranular water-soluble ingredients,

wherein the master granule component is present in a mixture with the extragranular component in the lozenge composition,

wherein the one or more non-dissolved solid particles are selected from one or more sugars or one or more sugar alcohols, and

wherein a weight ratio of the master granule component premixture relative to the extragranular component is from 1:30 to 1:2.

16 . The lozenge composition according to claim 15 , wherein the weight ratio of the master granule component premixture relative to the extragranular component is from 1:20 to 1:3.

17 . The lozenge composition according to claim 15 , wherein the one or more cannabinoids are applied in a layer to the surface of the one or more non-dissolved solid particles comprised in the master granule component premixture before blending with the extragranular component.

18 . The lozenge composition according to claim 15 , wherein the lozenge composition does not comprise a polymer carrier for the one or more cannabinoids.

19 . The lozenge composition according to claim 15 , wherein the one or more cannabinoids comprises at least one isolated cannabinoid.

20 . The lozenge composition according to claim 15 , wherein the one or more non-dissolved solid particles comprises one or more sugar alcohols in an amount of 5 to 40% by weight of the powder composition and the one or more extragranular water-soluble ingredients comprises one or more sugar alcohols in an amount of 60 to 95% by weight of the of the lozenge composition.

21 . The lozenge composition according to claim 15 , wherein the one or more non-dissolved solid particles comprises one or more sugar alcohols in an amount of 20 to 40% by weight of the powder composition and the one or more extragranular water-soluble ingredients comprises one or more sugar alcohols in an amount of 60 to 80% by weight of the of the lozenge composition.

22 . The lozenge composition according to claim 15 , wherein the one or more non-dissolved solid particles are selected from the group consisting of xylitol, lactitol, sorbitol, maltitol, erythritol, isomalt and mannitol, and mixtures and combinations thereof.

23 . The lozenge composition according to claim 15 , wherein the one or more cannabinoids is selected from the group consisting of cannabidiol (CBD), cannabidiolic acid (CBDA), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabielsoin (CBE), iso-tetrahydrocannabinol (iso-THC), cannabicyclol (CBL), cannabicitran (CBT), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), and mixtures and combinations thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2022
From: FERTIN PHARMA A/S
To: MEDCAN PHARMA A/S
Reel/Frame 060479/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2022
From: FERTIN PHARMA A/S
To: NORDICCAN A/S
Reel/Frame 060481/0573 →
CHANGE OF NAME Recorded Jul 12, 2022
From: MEDCAN PHARMA A/S
To: NORDICCAN A/S
Reel/Frame 060635/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2022
From: BRUUN, HEIDI ZIEGLER; BOESEN, DORTHE SCHACKINGER; ERIKSEN, ANE
To: FERTIN PHARMA A/S
Reel/Frame 059283/0763 →
Priority Claims (1)
CA 3040547 · Apr 17, 2019 · national
Continuity (2)
Continuation 16852133 · Apr 17, 2020
Related Publication 20220110912A1 · Apr 14, 2022
References Cited (39)
US 6730330B2 · Whittle et al. · 2004 [cited by applicant]
US 8735374B2 · Zerbe et al. · 2014 [cited by applicant]
US 9308175B2 · Pellikaan · 2016 [cited by examiner]
US 10137161B2 · Kolsky · 2018 [cited by applicant]
US 10434084B2 · Raber et al. · 2019 [cited by examiner]
US 20100034888A1 · Pellikaan et al. · 2010 [cited by applicant]
US 20120276199A1 · Bondu et al. · 2012 [cited by applicant]
US 20160015683A1 · McCarty · 2016 [cited by examiner]
US 20160220593A1 · Anastassov · 2016 [cited by examiner]
US 20170157041A1 · Goldner · 2017 [cited by applicant]
US 20170368020A1 · Estey et al. · 2017 [cited by applicant]
US 20180042842A1 · Whittle et al. · 2018 [cited by applicant]
US 20180071350A1 · Kolsky · 2018 [cited by applicant]
US 20180169035A1 · Eyal · 2018 [cited by examiner]
US 20180193392A1 · Silver · 2018 [cited by applicant]
US 20180221304A1 · Small-Howard et al. · 2018 [cited by applicant]
US 20200061022A1 · Nowak et al. · 2020 [cited by applicant]
US 20200316012A1 · Schou · 2020 [cited by applicant]
CA 2664311C · 2015 [cited by applicant]
CA 3028973A1 · 2017 [cited by applicant]
EP 2298284A2 · 2011 [cited by examiner]
EP 2061427B1 · 2011 [cited by applicant]
WO 2004096184A1 · 2004 [cited by applicant]
WO 2009134947A1 · 2009 [cited by applicant]
WO 2013169101A1 · 2013 [cited by applicant]
WO 2016126592A1 · 2016 [cited by applicant]
WO 2017183011A1 · 2017 [cited by applicant]
WO 2017202424A1 · 2017 [cited by applicant]
WO 2017223309A1 · 2017 [cited by applicant]
WO 2018022669A1 · 2018 [cited by applicant]
WO 2018089863A1 · 2018 [cited by applicant]
WO 2018142403A1 · 2018 [cited by applicant]
WO 2018144637A1 · 2018 [cited by applicant]
Lumír Ondřej Hanuš, Terpenes/Terpenoids in Cannabis: Are They Important?, Med Cannabis Cannabinoids 2020;3:25-60 (Year: 2020). [cited by examiner]
Do Terpenes Classify as Lipids? Terpene Classification, Floraplex Terpenes, downloaded in Nov. 2023 (Year: 2023). [cited by examiner]
Wade et al., “A multicentre, randomised, double-blind, single-dose study assessing the efficacy of AMC/DCBA Warm ozenge or AMC/DC BA Cool lozenge in the relief of acute sore throat”, pub. date: Feb. 18, 2011 (Year: 2011… [cited by applicant]
Link et al., “Fluidized bed spray granulation: Investigation of the coating process on a single sphere”, publication date: Dec. 1997 ( Year: 1997). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/DK2020/050098 dated Jul. 17, 2020. [cited by applicant]
Kinghorn, et al. (editors), Phytocannabinoids, vol. 103, Progress in the Chemistry of Organic Natural Products, Contents, “Phytochemistry of [cited by applicant]